Pharmacokinetic study of high-dose oral rifampicin in critically Ill patients with multidrug-resistant Acinetobacter baumannii infection.
Hossein Karballaei-MirzahosseiniRomina Kaveh-AhangaranBita ShahramiMohammad Reza RouiniAtabak NajafiArezoo AhmadiSima SadraiAmirmahdi MojtahedzadehFarhad NajmeddinMojtaba MojtahedzadehPublished in: Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences (2022)
In critically ill patients with MDR-AB infections, neither fasting nor non-fasting administrations of high-dose oral RIF achieve the therapeutic aims. More research is needed in larger populations and with measuring the amount of protein-unbound RIF levels.
Keyphrases
- multidrug resistant
- high dose
- acinetobacter baumannii
- pulmonary tuberculosis
- drug resistant
- gram negative
- low dose
- stem cell transplantation
- blood glucose
- klebsiella pneumoniae
- mycobacterium tuberculosis
- insulin resistance
- pseudomonas aeruginosa
- protein protein
- metabolic syndrome
- amino acid
- type diabetes
- escherichia coli
- cystic fibrosis